Septic Shock Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major septic shock markets are expected to exhibit a CAGR of 6.53% during 2024-2034.
The septic shock market has been comprehensively analyzed in IMARC's new report titled "Septic Shock Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Septic shock refers to a life-threatening condition that occurs when the body's immune response to an infection becomes overwhelming and causes widespread inflammation throughout the body. The symptoms of the ailment can develop rapidly and include fever, chills, rapid heart rate, confusion or disorientation, decreased urine output, abdominal pain, nausea, vomiting, skin rash, etc. As the condition progresses, septic shock can lead to severe hypotension, respiratory failure, acute kidney injury, and cardiac arrest. The diagnosis of the ailment is based on a combination of clinical evaluation and laboratory testing. Medical professionals will evaluate the patient's symptoms and perform a physical examination, including monitoring blood pressure, heart rate, respiratory rate, etc. Blood tests help in identifying the presence of an infection as well as markers of inflammation and organ dysfunction. Several imaging studies, such as chest X-rays or CT scans, are also used to locate the source of the infection. In some cases, medical professionals may perform various invasive procedures, including blood cultures and a lumbar puncture, to help identify the specific organism causing the infection.
The increasing cases of bacterial, fungal, viral, and parasitic infections, which lead to systemic inflammation as well as widespread organ dysfunction, are primarily driving the septic shock market. Additionally, the rising prevalence of various associated risk factors, including advancing age, weakened immune system, chronic illness, invasive medical procedures, etc., is also bolstering the market growth. Moreover, the escalating adoption of broad-spectrum antibiotics to control the infection and prevent further damage to the body is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of vasopressors, such as norepinephrine, epinephrine, dopamine, etc., since they increase blood pressure and enhance blood flow to vital organs, is creating a positive outlook for the market. Furthermore, numerous key players are making extensive investments in the development of biomarkers that can aid in the diagnosis, risk stratification, and monitoring of septic shock patients. This, in turn, is also propelling the market growth. Additionally, the inflating utilization of immunomodulation agents, including corticosteroids, intravenous immunoglobulin, granulocyte-macrophage colony-stimulating factor, etc., to modulate the immune response and restore immune homeostasis is expected to drive the septic shock market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the septic shock market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for septic shock and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the septic shock market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the septic shock market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the septic shock market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current septic shock marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the septic shock market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the septic shock market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the septic shock market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of septic shock across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of septic shock by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of septic shock by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with septic shock across the seven major markets?
What is the size of the septic shock patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of septic shock?
What will be the growth rate of patients across the seven major markets?
Septic Shock: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for septic shock drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the septic shock market?
What are the key regulatory events related to the septic shock market?
What is the structure of clinical trial landscape by status related to the septic shock market?
What is the structure of clinical trial landscape by phase related to the septic shock market?
What is the structure of clinical trial landscape by route of administration related to the septic shock market?
The septic shock market has been comprehensively analyzed in IMARC's new report titled "Septic Shock Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Septic shock refers to a life-threatening condition that occurs when the body's immune response to an infection becomes overwhelming and causes widespread inflammation throughout the body. The symptoms of the ailment can develop rapidly and include fever, chills, rapid heart rate, confusion or disorientation, decreased urine output, abdominal pain, nausea, vomiting, skin rash, etc. As the condition progresses, septic shock can lead to severe hypotension, respiratory failure, acute kidney injury, and cardiac arrest. The diagnosis of the ailment is based on a combination of clinical evaluation and laboratory testing. Medical professionals will evaluate the patient's symptoms and perform a physical examination, including monitoring blood pressure, heart rate, respiratory rate, etc. Blood tests help in identifying the presence of an infection as well as markers of inflammation and organ dysfunction. Several imaging studies, such as chest X-rays or CT scans, are also used to locate the source of the infection. In some cases, medical professionals may perform various invasive procedures, including blood cultures and a lumbar puncture, to help identify the specific organism causing the infection.
The increasing cases of bacterial, fungal, viral, and parasitic infections, which lead to systemic inflammation as well as widespread organ dysfunction, are primarily driving the septic shock market. Additionally, the rising prevalence of various associated risk factors, including advancing age, weakened immune system, chronic illness, invasive medical procedures, etc., is also bolstering the market growth. Moreover, the escalating adoption of broad-spectrum antibiotics to control the infection and prevent further damage to the body is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of vasopressors, such as norepinephrine, epinephrine, dopamine, etc., since they increase blood pressure and enhance blood flow to vital organs, is creating a positive outlook for the market. Furthermore, numerous key players are making extensive investments in the development of biomarkers that can aid in the diagnosis, risk stratification, and monitoring of septic shock patients. This, in turn, is also propelling the market growth. Additionally, the inflating utilization of immunomodulation agents, including corticosteroids, intravenous immunoglobulin, granulocyte-macrophage colony-stimulating factor, etc., to modulate the immune response and restore immune homeostasis is expected to drive the septic shock market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the septic shock market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for septic shock and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the septic shock market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the septic shock market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the septic shock market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current septic shock marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the septic shock market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the septic shock market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the septic shock market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of septic shock across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of septic shock by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of septic shock by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with septic shock across the seven major markets?
What is the size of the septic shock patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of septic shock?
What will be the growth rate of patients across the seven major markets?
Septic Shock: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for septic shock drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the septic shock market?
What are the key regulatory events related to the septic shock market?
What is the structure of clinical trial landscape by status related to the septic shock market?
What is the structure of clinical trial landscape by phase related to the septic shock market?
What is the structure of clinical trial landscape by route of administration related to the septic shock market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SEPTIC SHOCK - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SEPTIC SHOCK - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SEPTIC SHOCK - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 SEPTIC SHOCK - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SEPTIC SHOCK - UNMET NEEDS
10 SEPTIC SHOCK - KEY ENDPOINTS OF TREATMENT
11 SEPTIC SHOCK - MARKETED PRODUCTS
11.1 List of Septic Shock Marketed Drugs Across the Top 7 Markets
11.1.1 Giapreza (Angiotensin II) - La Jolla Pharmaceutical Company
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SEPTIC SHOCK - PIPELINE DRUGS
12.1 List of Septic Shock Pipeline Drugs Across the Top 7 Markets
12.1.1 Adrecizumab - Adrenomed
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Centhaquine - Pharmazz
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 OctaplasLG - Octapharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 GEM 00220 - Northern Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Nangibotide - Inotrem
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SEPTIC SHOCK - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SEPTIC SHOCK – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SEPTIC SHOCK - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Septic Shock - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Septic Shock - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Septic Shock - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Septic Shock - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Septic Shock - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Septic Shock - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Septic Shock - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Septic Shock - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Septic Shock - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Septic Shock - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Septic Shock - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Septic Shock - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Septic Shock - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Septic Shock - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Septic Shock - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Septic Shock - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Septic Shock - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Septic Shock - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Septic Shock - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Septic Shock - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Septic Shock - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Septic Shock - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Septic Shock - Access and Reimbursement Overview
16 SEPTIC SHOCK - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SEPTIC SHOCK MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SEPTIC SHOCK MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SEPTIC SHOCK - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SEPTIC SHOCK - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SEPTIC SHOCK - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 SEPTIC SHOCK - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SEPTIC SHOCK - UNMET NEEDS
10 SEPTIC SHOCK - KEY ENDPOINTS OF TREATMENT
11 SEPTIC SHOCK - MARKETED PRODUCTS
11.1 List of Septic Shock Marketed Drugs Across the Top 7 Markets
11.1.1 Giapreza (Angiotensin II) - La Jolla Pharmaceutical Company
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SEPTIC SHOCK - PIPELINE DRUGS
12.1 List of Septic Shock Pipeline Drugs Across the Top 7 Markets
12.1.1 Adrecizumab - Adrenomed
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Centhaquine - Pharmazz
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 OctaplasLG - Octapharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 GEM 00220 - Northern Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Nangibotide - Inotrem
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SEPTIC SHOCK - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SEPTIC SHOCK – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SEPTIC SHOCK - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Septic Shock - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Septic Shock - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Septic Shock - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Septic Shock - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Septic Shock - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Septic Shock - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Septic Shock - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Septic Shock - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Septic Shock - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Septic Shock - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Septic Shock - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Septic Shock - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Septic Shock - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Septic Shock - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Septic Shock - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Septic Shock - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Septic Shock - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Septic Shock - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Septic Shock - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Septic Shock - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Septic Shock - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Septic Shock - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Septic Shock - Access and Reimbursement Overview
16 SEPTIC SHOCK - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SEPTIC SHOCK MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SEPTIC SHOCK MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
